Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and keeping the ...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Oct 2 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its ...

US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries. The announcement ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Perrigo Company (PRGO – Research Report) today and set a price target of ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.